Login to Your Account

LONDON – Moves to increase patient involvement in drug development will ramp up in the next few months as the European Patients' Academy on Therapeutic Innovation (Eupati) enrolls 60 new students to its expert training course and launches an online toolbox of educational resources for patient advocates.
Analysts mulled what the approval in the European Union (EU) of Amgen Inc.'s cholesterol drug Repatha (evolocumab) might mean for the compound's fate in the U.S., and for same-class competitor Praluent (alirocumab) from Regeneron Pharmaceuticals Inc. and Sanofi SA in both regions.
LONDON – The extent to which big pharma has piled into rare disease research is highlighted in a new study of patents in the field launched at the Biotechnology Industry Organization meeting on Monday.
More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: